Gabapentin Market Report 2026

Gabapentin Market Overview

• Gabapentin market size has reached to $3.01 billion in 2025 • Expected to grow to $4.45 billion in 2030 at a compound annual growth rate (CAGR) of 8.1% • Growth Driver: The Increasing Prevalence Of Epilepsy Is Fueling The Growth Of The Market Due To Rising Cases Driven By An Aging Population And The Need For Effective Seizure Control • Market Trend: Advancements In Bioequivalent Gabapentin Tablets Boost Neurological Treatment Options • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Gabapentin Market?

Gabapentin is a prescription medication that is primarily used to treat nerve pain, epilepsy, and restless legs syndrome. It targets nerve signals and brain chemicals to control seizures and ease nerve pain. It is widely used to treat nerve-related pain from shingles and diabetic neuropathy. Gabapentin helps stabilize brain activity and reduce abnormal nerve excitability. The main types of gabapentin are generic and branded. Generic drugs contain the same active ingredients and dosage as branded ones, providing a more affordable yet equally effective alternative for medications. It is available in various dosage forms such as tablets, capsules, and oral solution and is distributed through several distribution channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others, for various applications such as epilepsy, neuropathic pain, restless legs syndrome, and others.

What Is The Gabapentin Market Growth Forecast?

The gabapentin market size is expected to see strong growth in the next few years. It will grow to $4.45 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to aging population, diabetic neuropathy growth, generic penetration, outpatient pain management, telemedicine prescriptions. Major trends in the forecast period include rising use in neuropathic pain management, increased demand for generic formulations, expansion of chronic pain treatment programs, growth of oral solid dosage forms, increased prescriptions for neurological disorders.

What Is The Driver Of The Gabapentin Market?

The increasing prevalence of epilepsy is expected to drive the growth of the gabapentin market going forward. Epilepsy is a brain disorder characterized by repeated seizures caused by irregular electrical activity in the brain. Epilepsy cases are rising mainly due to the growing elderly population, as aging increases the risk of neurological disorders that cause seizures. Gabapentin controls epilepsy by calming abnormal nerve activity in the brain and lowering seizure-causing signals. It works by targeting calcium channels to help prevent seizure occurrence. For instance, in February 2024, according to the World Health Organization (WHO), a Switzerland-intergovernmental organization, around 50 million people globally have epilepsy, nearly 80% of those with epilepsy live in low- and middle-income countries, and up to 70% could live seizure-free if properly diagnosed and treated. Each year, an estimated 5 million people are newly diagnosed with epilepsy worldwide; in high-income countries this rate is about 49 per 100,000, while in low- and middle-income countries it can be as high as 139 per 100,000. Therefore, the increasing prevalence of epilepsy is driving the growth of the gabapentin industry.

Key Players In The Global Gabapentin Market

Major companies operating in the gabapentin market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan Inc., Apotex Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., Ipca Laboratories Private Limited, Granules India Limited, Medley Pharmaceuticals Limited, Wockhardt Limited, Epic Pharma LLC, Healing Pharma India Pvt. Ltd., Rochem International Inc., Accord Healthcare Limited, Strides Pharma Science Limited, Ascend Laboratories LLC

Global Gabapentin Market Trends and Insights

Major companies operating in the gabapentin market are focusing on developing advanced formulations, such as bioequivalent tablets, to enhance therapeutic efficacy and expand treatment options for neurological conditions. Bioequivalent tablets are generic drugs that release an identical dose of the active ingredient into the bloodstream with the same speed and efficiency as the branded version, guaranteeing similar safety and therapeutic effects. For instance, in March 2024, Strides Pharma Science Limited, an India-based pharmaceutical company, launched Gabapentin Tablets USP in 600 mg and 800 mg strengths, which received approval from the United States Food & Drug Administration (USFDA) to expand the neurology portfolio in the US market. This innovative gabapentin features enhanced bioavailability, precise dosing, and patient-friendly administration, enabling more consistent therapeutic outcomes, improved symptom control, and greater convenience for long-term therapy. Gabapentin tablets USP, 600 mg, offer versatile therapeutic potential, providing effective management of a range of neurological conditions such as neuropathic pain and partial seizures through reliable dosing and proven clinical efficacy.

What Are Latest Mergers And Acquisitions In The Gabapentin Market?

In September 2023, Adalvo, a Malta-based pharmaceutical company, collaborated with Lotus Pharmaceutical to enhance lives through accessible and innovative neurological care. The partnership aims to offer a convenient, once-daily treatment for postherpetic neuralgia by launching Gabapentin ER in South Korea, addressing unmet needs, and expanding its market presence in neurology. Lotus Pharmaceutical is a Taiwan-based manufacturer of gabapentin extended-release tablets.

What Defines the Gabapentin Market?

The gabapentin market consists of sales of gabapentin immediate-release, gabapentin extended-release, and oral solution. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Gabapentin Market Report 2026?

The gabapentin market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gabapentin industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.